Activation of the Human Complement System by Cholesterol-Rich and PEGylated Liposomes—Modulation of Cholesterol-Rich Liposome-Mediated Complement Activation by Elevated Serum LDL and HDL Levels

References

• Alberts D. S., Garcia D. J. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997; 54(Suppl.)30–45, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Andresen T. L., Davidsen J., Begtrup M., Mouritsen O. G., Jørgensen K. Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs. J. Med. Chem 2004; 47: 1694–1703, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A., Szebeni J., Savay S., Liebes L., Rafique N. M., Alving C. R., Muggia F. M. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Annal. Oncology 2003; 14: 1430–1437, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chonn A., Cullis P. R., Devine D. V. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol 1991; 146: 4234–4241, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dezube B. J. Safety assessment: Doxil® (doxorubicin HCl liposome injection) in refractory AIDS-related Kaposi's sarcoma. Doxil Clinical Series. Gardiner-Caldwell SynerMed, Califon, NJ 1996; 1–8
   Google Scholar
• Kent K. M., Cleman M. W., Cowley M. J., Forman M. B., Jaffe C. C., Kaplan M., King S. B., Krucoff M. W., Lassar T., Mcauley B., Smith R., Wisdom C., Wohlgelernter D. Reduction of myocardial ischemia during percutaneous coronary angioplasty with oxygenated Fluosol. Am. J. Cardiol 1990; 66: 279–284, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Levine S. J., Walsh T. J., Martinez A., Eichacker P. Q., Lopez-Berstein G., Natanson C. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann. Intern. Med 1991; 114: 664–666, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lustig R., McIntosh-Lowe N., Rose C., Haas J., Krasnow S., Spaulding M., Prosnitz L. Phase I/II study of Fluosol-DA and 100% oxygen as an adjuvant to radiation in the treatment of advanced squamous cell tumours of the head and neck. Int. J. Radiat. Oncol. Biol. Phys 1989; 16: 1587–1593, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lutz H. U., Stammler P., Jelezarova E., Nater M., Spath P. J. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 1996; 88: 184–193, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• McLoughlin T. M., Fontana J. L., Alving C. R., Mongan P. D., Bünger R. Profound normovolemic hemodilution: hemostatic effects in patients and in a porcine model. Anesth. Analg 1996; 83: 459–465, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Moghimi S. M., Andresen T. L., Jørgensen K., Szebeni J. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production in human serum. 2006, (Submitted)[CSA]
   Google Scholar
• Moghimi S. M., Hunter A. C. Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups. Pharm. Res 2001; 18: 1–8, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Moghimi S. M., Hunter A. C., Dadswell C. M., Savay S., Alving C. R., Szebeni J. Causative factors behind poloxamer 188 (Pluronic F68, Flocor™)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels. Biochim. Biophys. Acta (Mol. Basis Disease) 2004; 1689: 103–113, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Moghimi S. M., Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res 2003; 42: 463–478, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Moore F. D., Jr. Therapeutic regulation of the complement system in acute injury states. Adv. Immunol 1994; 56: 267–299, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Police A. M., Waxman K., Tominaga G. Pulmonary complications after Fluosol administration to patients with life-threatening blood loss. Crit. Care Med 1985; 13: 96–98, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ringdén O., Andström E., Remberger M., Svahn B. M., Tollemar J. Allergic reactions and other rare side effects of liposomal amphotericin. Lancet 1994; 344: 1156–1157, [CSA]
   PubMed Web of Science ®Google Scholar
• Szebeni J., Baranyi B., Savay S., Bodo M., Morse D. S., Basta M., Stahl G. L., Bunger R., Alving C. R. Liposome-induced pulmonary hypertension in pigs: properties and mechanism of a complement-mediated pseudoallergic reaction. Am. J. Physiol. (Heart Circ. Physiol.) 2000a; 279: H1319–H1328, [CSA]
   PubMed Web of Science ®Google Scholar
• Szebeni J., Baranyi L., Savay S., Lutz H. U., Jelezarova E., Bunger R., Alving C. R. The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (Doxil®). J. Liposome Res 2000; 10: 469–481, [CSA]
   Web of Science ®Google Scholar
• Szebeni J., Baranyi L., Savay S., Milosevits J., Bubger R., Laverman P., Metselaar J. M., Storm G., Chanan-Khan A., Liebes L., Muggia F. M., Cohen R., Barenholz Y., Alving C. R. Role of complement activation in hypersensitivity reactions to doxil and HYNICPEG liposomes: experimental and clinical studies. J. Liposome Res 2002; 12: 165–172, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Szebeni J., Fontana J. L., Wassef N. M., Mongan P. D., Morse D. S., Dobbins D. E., Stahl G. L., Bünger R., Alving C. R. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs. A model for pseudoallergic cardiopulmonary reactions to liposomes: role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 1999; 99: 2302–2309, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tremper K. K., Friedman A. E., Levine E. M., Lapin R., Camarillo D. The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid, Fluosol-DA. N. Engl. J. Med 1984; 12: 428–431, [CSA]
   Google Scholar
• Vercellotti G. M., Hammerschmidt D. E., Craddock P. R., Jacob H. S. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroid prophylaxis. Blood 1982; 59: 1299–1304, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Zakharov A. T. S., Ivanov A. S., Echkalov A. P., Berezov A. T., Khalilov E. M., Archakov A. I. Effect of the cholesterol content in liposomes on their interaction with blood-serum lipoproteins. Biochemistry (Moscow) 1994; 59: 525–530, [CSA]
   Web of Science ®Google Scholar